Announcements Trials

Conditions

Other 5Lymphoid 3Dermatologic 1

Drug Classes

Anti-CD19 CAR T-cell 14Anti-CD20 14BTK inhibitor 13Anti-CD20-CD3 bispecific 5Anti-CD30 ADC 5Immunomodulatory drugs (IMiDs) 5Anti-PD-1 4Bcl-2 inhibitor 4Nitrogen mustard 3PI3K delta inhibitor 3Anthracycline 2Anti-CD19 2Anti-CD19-CD3 bispecific 2Anti-CD22 ADC 2Anti-CD79B ADC 2Asparagine-specific enzyme 2ALK inhibitor 1Anti-CCR4 1Anti-CD19 ADC 1Anti-CD22 immunotoxin 1Bcr-Abl inhibitor 1EZH inhibitor 1FGFR inhibitor 1HDAC inhibitor 1KMT2A inhibitor 1Proteasome inhibitor 1XPO1 inhibitor 1
Nitrogen mustard × Lymphoid × Clear all

3 Announcements

2025-01-16

FDA approves acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma

Drugs
Calquence (acalabrutinib) · BTK inhibitor, bendamustine · Nitrogen mustard, rituximab · Anti-CD20 antibody
Condition
Lymphoid
2019-06-10

FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma

Drugs
POLIVY (polatuzumab vedotin-piiq) · Anti-CD79B antibody-drug conjugate, bendamustine · Nitrogen mustard, rituximab · Anti-CD20 antibody
Condition
Lymphoid
2006-02-10

FDA approves rituximab (Rituxan) for use in the first‑line treatment of patients with diffuse large B-cell, CD20‑positive, non-Hodgkin's lymphoma in combination with CHOP or other anthracycline‑based chemotherapy regimens

Drugs
Rituxan (rituximab) · Anti-CD20 antibody, cyclophosphamide · Nitrogen mustard
Condition
Lymphoid
Data powered by HemOnc (CC BY 4.0) Colophon ⚡